VANDA PHARMACEUTICALS INC. Increase (Decrease) in Deferred Revenue
VANDA PHARMACEUTICALS INC. (VNDA) reported Increase (Decrease) in Deferred Revenue of $314.00 thousand for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-07-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2017-02-17
- VANDA PHARMACEUTICALS INC. increase (decrease) in deferred revenue for the quarter ending 2015-06-30 was $75.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in deferred revenue for the quarter ending 2015-03-31 was $239.00K.
- VANDA PHARMACEUTICALS INC. increase (decrease) in deferred revenue for the quarter ending 2014-12-31 was -$7.59M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in deferred revenue for the quarter ending 2014-09-30 was -$7.76M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in deferred revenue for fiscal 2014 was -$30.57M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in deferred revenue for fiscal 2013 was -$26.79M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in deferred revenue for fiscal 2012 was -$26.79M.
- VANDA PHARMACEUTICALS INC. increase (decrease) in deferred revenue for fiscal 2011 was -$26.79M.
| Period end | Increase (Decrease) in Deferred Revenue 3 month | Increase (Decrease) in Deferred Revenue 6 month | Increase (Decrease) in Deferred Revenue 9 month | Increase (Decrease) in Deferred Revenue 9 month as first filed | Increase (Decrease) in Deferred Revenue 12 month |
|---|---|---|---|---|---|
| 2015-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | $314.00K 10-Q · filed 2015-07-31 | -$7.28M derived: sum of 3 quarters · filed 2017-02-17 | -$15.04M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2015-03-31 | $239.00K 10-Q · filed 2015-05-07 | -$7.35M derived: sum of 2 quarters · filed 2017-02-17 | -$15.12M derived: sum of 3 quarters · filed 2017-02-17 | -$22.88M derived: sum of 4 quarters · filed 2017-02-17 | |
| 2014-12-31 | -$7.59M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$15.36M derived: sum of 2 quarters · filed 2017-02-17 | -$23.12M derived: sum of 3 quarters · filed 2017-02-17 | -$30.57M 10-K · filed 2017-02-17 | |
| 2014-09-30 | -$7.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$15.53M derived: sum of 2 quarters · filed 2015-11-04 | -$22.98M 10-Q · filed 2015-11-04 | -$22.81M 10-Q · filed 2014-10-27 | -$29.73M derived: sum of 4 quarters · filed 2015-11-04 |
| 2014-06-30 | -$7.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-31 | -$15.22M 10-Q · filed 2015-07-31 | -$21.97M derived: sum of 3 quarters · filed 2015-07-31 | -$28.72M derived: sum of 4 quarters · filed 2015-07-31 | |
| 2014-03-31 | -$7.45M 10-Q · filed 2015-05-07 | -$14.20M derived: sum of 2 quarters · filed 2015-05-07 | -$20.96M derived: sum of 3 quarters · filed 2015-05-07 | -$27.64M derived: sum of 4 quarters · filed 2015-05-07 | |
| 2013-12-31 | -$6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | -$13.51M derived: sum of 2 quarters · filed 2015-03-13 | -$20.18M derived: sum of 3 quarters · filed 2015-03-13 | -$26.79M 10-K · filed 2015-03-13 | |
| 2013-09-30 | -$6.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-27 | -$13.43M derived: sum of 2 quarters · filed 2014-10-27 | -$20.04M 10-Q · filed 2014-10-27 | -$26.79M derived: sum of 4 quarters · filed 2015-03-13 | |
| 2013-06-30 | -$6.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-08 | -$13.28M 10-Q · filed 2014-08-08 | -$20.04M derived: sum of 3 quarters · filed 2015-03-13 | -$26.79M derived: sum of 4 quarters · filed 2015-03-13 | |
| 2013-03-31 | -$6.61M 10-Q · filed 2014-05-08 | -$13.36M derived: sum of 2 quarters · filed 2015-03-13 | -$20.11M derived: sum of 3 quarters · filed 2015-03-13 | -$26.79M derived: sum of 4 quarters · filed 2015-03-13 | |
| 2012-12-31 | -$6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | -$13.51M derived: sum of 2 quarters · filed 2015-03-13 | -$20.18M derived: sum of 3 quarters · filed 2015-03-13 | -$26.79M 10-K · filed 2015-03-13 | |
| 2012-09-30 | -$6.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08 | -$13.43M derived: sum of 2 quarters · filed 2013-11-08 | -$20.04M 10-Q · filed 2013-11-08 | -$26.79M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-06-30 | -$6.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | -$13.28M 10-Q · filed 2013-07-31 | -$20.04M derived: sum of 3 quarters · filed 2014-02-25 | -$26.79M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2012-03-31 | -$6.61M 10-Q · filed 2013-05-10 | -$13.36M derived: sum of 2 quarters · filed 2014-02-25 | -$20.11M derived: sum of 3 quarters · filed 2014-02-25 | -$26.79M derived: sum of 4 quarters · filed 2014-02-25 | |
| 2011-12-31 | -$6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | -$13.51M derived: sum of 2 quarters · filed 2014-02-25 | -$20.18M derived: sum of 3 quarters · filed 2014-02-25 | -$26.79M 10-K · filed 2014-02-25 | |
| 2011-09-30 | -$6.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | -$13.43M derived: sum of 2 quarters · filed 2012-11-08 | -$20.04M 10-Q · filed 2012-11-08 | -$26.79M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-06-30 | -$6.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | -$13.28M 10-Q · filed 2012-08-03 | -$20.04M derived: sum of 3 quarters · filed 2013-02-26 | -$26.79M derived: sum of 4 quarters · filed 2013-02-26 | |
| 2011-03-31 | -$6.61M 10-Q · filed 2012-05-09 | -$13.36M derived: sum of 2 quarters · filed 2013-02-26 | -$20.11M derived: sum of 3 quarters · filed 2013-02-26 | ||
| 2010-12-31 | -$6.75M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | -$13.51M derived: sum of 2 quarters · filed 2013-02-26 | -$26.79M 10-K · filed 2013-02-26 | ||
| 2010-09-30 | -$6.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$20.04M 10-Q · filed 2011-11-07 | |||
| 2010-06-30 | -$13.28M 10-Q · filed 2011-08-05 | ||||
| 2009-12-31 | $197.43M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |